Table 1.
Demographic and clinical characteristics of participants.
| HC (n = 34) | IgAN patients (n = 74) | |||
|---|---|---|---|---|
| Stage I+II (n = 26) | Stage III (n = 29) | Stage IV+V (n = 19) | ||
| Age, year | 43 (18–76) | 37 (17–69) | 46 (19–72) | 42 (23–77) |
| Female/male | 15/19 | 14/12 | 16/13 | 8/11 |
| Lymphocytes, 109/L | 1.72 (0.84–2.87) | 1.68 (0.87–3.22) | 2.04 (0.82–4.13) | 2.12 (0.89–3.92) |
| Serum albumin, g/L | 43.2 (40.8–50.6) | 35.3 (14.3–41.4)∗ | 33.2 (8.84–39.6)∗ | 30.24 (12.1–38.9)∗ |
| Serum uric acid, μmol/L | 305 (245–416) | 342 (231–604) | 371 (252–611) | 383 (247–584) |
| Triglycerides, mmol/L | 1.27 (0.51–1.78) | 2.32 (0.62–6.53) | 2.56 (0.58–4.78) | 2.23 (0.74–4.94) |
| Cholesterol, mmol/L | 4.07 (2.86–5.47) | 5.12 (3.12–8.78) | 6.24 (3.23–9.14) | 5.85 (2.86–10.05) |
| Urinary proteins, g/24 h | 0.048 (0–0.12) | 2.61 (0.65–4.13)∗ | 3.46 (0.52–6.36)∗ | 3.17 (0.71–5.89)∗ |
| Urea nitrogen, mmol/L | 5.14 (3.62–6.68) | 5.95 (2.65–13.1) | 6.46 (3.13–10.35) | 6.87 (4.02–12.8) |
| eGFR, mL/min/1.73 m2 | 104.5 (88.5–112.4) | 89.4 (41.6–117.3)∗ | 74.2 (45.1–113.8)∗ | 60.7 (18.3–102.9)∗ |
| Microscopic hematuria, rbc/hpf | 1.1 (0–2.4) | 7.1 (0.2–23.4)∗ | 7.8 (0.8–27.6)∗ | 8.5 (1.2–19.4)∗ |
| Serum calcium, mmol/L | 2.38 (1.91–2.62) | 1.91 (1.48–2.35)∗ | 1.82 (1.52–2.23)∗ | 1.86 (1.56–2.43)∗ |
| Serum phosphorus, mmol/L | 1.15 (0.74–1.49) | 1.44 (0.84–1.91)∗ | 1.58 (0.81–2.12)∗ | 1.52 (0.93–2.04)∗ |
| Serum IgA, g/L | 1.87 (1.03–2.98) | 3.16 (1.78–4.85)∗ | 3.34 (1.45–4.97)∗ | 3.52 (1.39–4.79)∗ |
Data shown are median and range, except specified. ∗ p < 0.05 versus the HC.